Johnson & Johnson (JNJ) and Eli Lilly (LLY) represent two different logics in healthcare investing: the former is known for diversification and steady cash flow, while the latter wins by concentrating its bets on high-growth tracks. Eli Lilly’s valuation premium is obvious, but it corresponds to faster growth expectations; Johnson & Johnson offers a more balanced risk-return profile. For long-term investors, whether they are willing to pay a higher price for growth over the next several years is the core trade-off between these two stocks.
Johnson & Johnson operates through two major segments, Innovative Medicine and MedTech, covering hospitals, wholesalers, and healthcare professionals worldwide, and collaborates with partners such as AbbVie (ABBV) to promote key oncology therapies. It maintains leadership in immunology, neuroscience, and cardiovascular health. In fiscal year 2025, Johnson & Johnson’s revenue was approximately $94 billion, up 6% year over year; net profit was nearly $27 billion, with a net profit margin of about 29%. As of December 2025, its debt-to-equity ratio was about 0.6 times, its current ratio was about 1.0 times, and its free cash flow was nearly $19.7 billion. Johnson & Johnson faces intense competition from rivals of all sizes, pressure from generic drugs due to patent expirations, and must also address legal liabilities related to talc-containing products, as well as risks such as the divestiture of its orthopedics business and the execution of price reduction requirements under the Inflation Reduction Act.
Eli Lilly focuses on cardiometabolic health, oncology, and neuroscience, with key efforts in diabetes and obesity treatments. It distributes globally through major wholesalers such as McKesson (MCK) and also supplies drugs directly to patients through the LillyDirect digital platform. In fiscal year 2025, Eli Lilly’s revenue was approximately $65.2 billion, surging 45% year over year; net profit was about $20.6 billion, with a net profit margin of nearly 32%, and net profit nearly doubled year over year. As of December 2025, its current ratio was about 1.6 times, its debt-to-equity ratio was about 1.6 times, and its free cash flow was nearly $9 billion. Eli Lilly relies heavily on a small number of cardiometabolic products, with about 82% of revenue in 2025 coming from this area, making it vulnerable to intellectual property challenges and pricing pressure from government payers, while dependence on single-source suppliers and third-party manufacturers also creates supply chain bottleneck risks.
Johnson & Johnson is more like a conservative value choice, while Eli Lilly enjoys a higher premium due to aggressive growth. Johnson & Johnson’s forward price-to-earnings ratio is 22.7 times, and its price-to-sales ratio is 6.4 times; Eli Lilly’s are 31.4 times and 13.6 times, respectively. Johnson & Johnson’s revenue is expected to rise to $101 billion this fiscal year. Eli Lilly’s revenue in 2026 is expected to grow by as much as 30% to $85.2 billion, with net profit of nearly $31 billion.
